Michael J Overman, M.D.

Peer-Reviewed Articles

1. Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut 67(6):1095-1102, 2018. e-Pub 2017. PMID: 29084828.
2. Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Marchal F, Conrad C, Aloia TA, Vauthey JN, Chun YS, BIG-RENAPE Working Group. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. Ann Surg Oncol 25(1):179-187, 2018. e-Pub 2017. PMID: 29071660.
3. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2017. PMID: 29069279.
4. Yamashita S, Overman MJ, Wang H, Zhao J, Okuno M, Goumard C, Tzeng CW, Kim M, Fleming JB, Vauthey JN, Katz MH, Lee JE, Conrad C. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol 24(13):3954-3963, 2017. e-Pub 2017. PMID: 28980211.
5. Parseghian CM, Raghav K, Wolff RA, Ensor J, Yao J, Ellis LM, Tam AL, Overman MJ. Under-reporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res 23(21):6450-6457, 2017. e-Pub 2017. PMID: 28754815.
6. Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol 24(12):3667-3672, 2017. e-Pub 2017. PMID: 28831698.
7. Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg 152(11):1048-1056, 2017. e-Pub 2017. PMID: 28700784.
8. Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol 3(11):1546-1553, 2017. e-Pub 2017. PMID: 28617917.
9. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182-1191, 2017. e-Pub 2017. PMID: 28734759.
10. Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol 24(9):2646-2654, 2017. e-Pub 2017. PMID: 28695394.
11. Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clin Cancer Res 23(16):4578-4591, 2017. e-Pub 2017. PMID: 28400427.
12. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
13. Vauthey JN, Mizuno T, Overman MJ, Soubrane O. Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?. J Hepatol 67(1):10-11, 2017. e-Pub 2017. PMID: 28476639.
14. Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient Derived Xenografts in Colorectal Cancer. Mol Cancer Ther 16(7):1435-1442, 2017. e-Pub 2017. PMID: 28468778.
15. Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol 24(7):2031-2039, 2017. e-Pub 2017. PMID: 28124275.
16. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. e-Pub 2017. PMID: 28424412.
17. Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer 17(1):331, 2017. e-Pub 2017. PMID: 28506255.
18. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 10(1002):1011-1017, 2017. e-Pub 2016. PMID: 27859010.
19. Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. High Prevalence of Mutant KRAS in Circulating Exosome-derived DNA from Early Stage Pancreatic Cancer Patients. Ann Oncol 28(4):741-747, 2017. e-Pub 2017. PMID: 28104621.
20. Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru D, Overman MJ, Brudvik KW, Conrad C, Aloia TA, Vauthey JN. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery 161(2):332-340, 2017. e-Pub 2016. PMID: 27592215.
21. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One 12(8):e0183949, 2017. e-Pub 2017. PMID: 28850629.
22. Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol 122(1):146-151, 2017. e-Pub 2017. PMID: 28057329.
23. Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg 21(1):164-174, 2017. e-Pub 2016. PMID: 27778257.
24. Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen HC, Overman M, Raghav K, Eng C, Mansfield P, Royal R. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol 24(1):187-193, 2017. e-Pub 2016. PMID: 27660258.
25. Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg 20(12):1975-1985, 2016. e-Pub 2016. PMID: 27730398.
26. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
27. Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget 7(41):67495-67506, 2016. PMID: 27542211.
28. Grotz TE, Mansfield PF, Royal RE, Mann GN, Rafeeq S, Beaty KA, Overman MJ, Fournier KF. Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. Ann Surg Oncol 23(9):2914-9, 2016. e-Pub 2016. PMID: 27027310.
29. Passot G, Chun YS, Kopetz SE, Overman MJ, Conrad C, Aloia TA, Vauthey JN. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol 42(9):1378-84, 2016. e-Pub 2016. PMID: 27358198.
30. Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer 122(17):2671-9, 2016. e-Pub 2016. PMID: 27243381.
31. Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang ZQ, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer 114(12):1352-61, 2016. e-Pub 2016. PMID: 27272216.
32. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer 15(2):e1-7, 2016. e-Pub 2015. PMID: 26810202.
33. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther 15(6):1397-404, 2016. e-Pub 2016. PMID: 27207774.
34. Link JT, Overman MJ. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. Cancer J 22(3):190-5, 2016. PMID: 27341597.
35. Hoffmann MS, Overman MJ, Nates JL. Acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. J Community Support Oncol 14(4):178-9, 2016. PMID: 27152518.
36. Gingras MC, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot E, Dewal N, Fisher WE, Australian Pancreatic Cancer Genome Initiative, Pilarsky C, Grützmann R, Overman MJ, Jamieson NB, Van Buren G, Drummond J, Walker K, Hampton OA, Xi L, Muzny DM, Doddapaneni H, Lee SL, Bellair M, Hu J, Han Y, Dinh HH, Dahdouli M, Samra JS, Bailey P, Waddell N, Pearson JV, Harliwong I, Wang H, Aust D, Oien KA, Hruban RH, Hodges SE, McElhany A, Saengboonmee C, Duthie FR, Grimmond SM, Biankin AV, Wheeler DA, Gibbs RA. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep 14(4):907-19, 2016. e-Pub 2016. PMID: 26804919.
37. Asare EA, Compton CC, Hanna NN, Kosinski LA, Washington MK, Kakar S, Weiser MR, Overman MJ. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer 122(2):213-21, 2016. e-Pub 2015. PMID: 26506400.
38. Overman MJ, Soifer HS, Schueneman AJ, Ensor J Jr, Adsay V, Saka B, Neishaboori N, Wolff RA, Wang H, Schnabel CA, Varadhachary G.. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer 16(668), 2016. PMID: 27549176.
39. Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, Wang H, Overman MJ, Varadhachary GR. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One 11(5):e0154985, 2016. e-Pub 2016. PMID: 27171493.
40. Chouhan J, Gupta R, Ensor J, Raghav K, Fogelman D, Wolff RA, Fisch M, Overman MJ.. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med 5(2):239-47, 2016. PMID: 26714799.
41. Li D, Pise MN, Overman MJ, Liu C, Tang H, Vadhan-Raj S, Abbruzzese JL. ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. Cancer Med 4(11):1651-8, 2015. e-Pub 2015. PMID: 26275671.
42. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol 33(31):3583-90, 2015. e-Pub 2015. PMID: 26304898.
43. Xia M, Overman MJ, Rashid A, Chatterjee D, Wang H, Katz MH, Fleming JB, Lee JE, Varadhachary GR, Wolff RA, Wang H. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol 46(9):1315-22, 2015. e-Pub 2015. PMID: 26165226.
44. Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs 33(4):977-84, 2015. e-Pub 2015. PMID: 26062928.
45. Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S, Beaty K, Phillips JK, Wolff RA, Mansfield PF, Eng C. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol 22(8):2578-84, 2015. e-Pub 2015. PMID: 25582740.
46. Dineen S, Lynch PM, Rodriguez-Bigas MA, Bannon S, Taggart M, Reeves C, Modaro C, Overman M, Chang GJ, Skibber JM, You YN. A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer. J Natl Compr Canc Netw 13(7):865-72, 2015.
47. Taggart MW, Abraham SC, Overman MJ, Mansfield PF, Rashid A. Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis. Arch Pathol Lab Med 139(6):782-90, 2015. PMID: 26030247.
48. Schueneman A, Goggins M, Ensor J, Saka B, Neishaboori N, Lee S, Maitra A, Varadhachary G, Rezaee N, Wolfgang C, Adsay V, Wang H, Overman MJ. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. Br J Cancer 10(172):1038, 2015. PMID: 25989273.
49. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
50. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112:1088-97, 2015. e-Pub 2015. PMID: 25688736.
51. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterization of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 2010. e-Pub 2009. PMID: 19935793.
52. Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, Ohinata A, Liu J, Wang X, Eng C. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 116(2):316-22, 2010. e-Pub 2009. PMID: 19904805.
53. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 2009. e-Pub 2009. PMID: 19470929.
54. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 27(16):2598-603, 2009. e-Pub 2009. PMID: 19164203.
55. Overman MJ. Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res 3(3):90-6, 2009. PMID: 19626152.
56. Overman M, Kopetz S. Picking the right road for metastatic colorectal cancer patients. Oncology (Williston Park) 22(13):1482-3, 2008. PMID: 19227576.
57. Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 26(33):5344-51, 2008. e-Pub 2008. PMID: 18936472.
58. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a Platinum Compound Improves Outcomes in Metastatic Small Bowel Adenocarcinoma. Cancer 113(8):2038-2045, 2008. PMID: 18759326.
59. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445-54, 2008. e-Pub 2008. PMID: 18528634.
60. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9, 2008. PMID: 18798063.
61. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: A report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 2008. PMID: 18794067.
62. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol 26(12):2000-5, 2008. PMID: 18421052.
63. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19(3):553-9, 2008. e-Pub 2007. PMID: 18083690.
64. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer 7(1):55-9, 2008. PMID: 18279578.
65. Overman MJ, Hoff PM. EGFR-targeted Therapies in Colorectal Cancer. Dis Colon Rectum 50(8):1-13, 2007. PMID: 17566832.
66. Overman M, Brass E. Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration. Thromb Haemost 92(4):886-7, 2004. PMID: 15499705.
67. David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, Nelson WG. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol 17(6):1077-86, 2000. PMID: 11078791.
68. Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270(41):23895-8, 1995. PMID: 7592576.
69. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2(8). e-Pub 2017. PMID: 28422758.
70. Fogelman DR, Morris J, Xiao L, Hassan M, Vadhan S, Overman M, Javle S, Shroff R, Varadhachary G, Wolff R, Vence L, Maitra A, Cleeland C, Wang XS. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. e-Pub 2017. PMID: 28111717.
71. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. e-Pub 2016. PMID: 27421137.

Invited Articles

1. Cusack JC, Overman MJ, Wolff RA. Diagnosis and staging of small bowel neoplasms. UpToDate.com, 2009.
2. Cusack JC, Overman MJ, Wolff RA. Epidemiology, clinical features, and types of small bowel neoplasms. UpToDate.com, 2009.
3. Cusack JC, Overman MJ, Wolff RA. Treatment of small bowel neoplasms. UpToDate.com, 2009.

Abstracts

1. Lieu C, Lambert L, Wolff RA, Eng C, Lin E, Rafeeq S, Fournier K, Royal R, Mansfield P, Overman MJ. The role of surgical cytoreduction and systemic chemotherapy in metastatic poorly differentiated or signet ring cell adenocarcinomas of the appendix. GI ASCO. 2010 28, 2010.
2. Overman MJ, Hu C, Wolff RA, Chang GJ. Impact of lymph node evaluation on survival for small bowel adenocarcinoma: Analysis of the surveillance, epidemiology, and end results. ASCO 2009 Annual Meeting, 2009.
3. Kazmi SM, Phan, Jhamb J, Mani M, Tetzlaff E, Lin E, Ajani J, Abbruzzese JL, Overman MJ. Toxicity and efficacy of a weekly based docetaxel, cisplatin, and 5FU(DCF) as first-line treatment of advanced gastric and esophageal cancer. GI ASCO 2009, 2009.
4. Shroff R, Javle M, Varadhachary G, Krishnan S, Crane C, Wen S, Abbruzzese J, Wolff R, Overman M,J. Improved relapse-free survival with the addition of systemic chemotherapy to adjuvant chemoradiation for high risk ampullary adenocarcinoma. GI ASCO 2009, 2009.
5. Kopetz S, Hoff PM, Eng C, Overman MJ, Glover KY, Chang DZ, Wolff RA, Abbruzzese JL, Ellis LM, Heymach JV. Levels of angiogenic cytokines prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab. GI ASCO 2009, 2009.
6. Overman MJ, Varadachary G, Lin E, Morris J, Adinin R, Abbruzzese JL, Wolff RA. Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater. ASCO 2008 26, 2008.

Letters to the Editor

1. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist 20: e3-4, 2015.
2. Overman M, Wang H, Varadhachary GR. Adjuvant chemotherapy for resected periampullary adenocarcinoma. JAMA 308: 1855; author reply 1855-6, 2012.
3. Raghav KP, Taggart MW, Fournier KF, Overman MJ. Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity?. J Am Coll Surg 212: 906; author reply 907, 2011.
4. Overman M, Wang H, Varadhachary G. Comment of Neoptolemos JP et al, JAMA 308:147-56, 2012. JAMA.